Richard Branson (John Raoux/AP Images)

The SPAC at­tack has just be­gun. And the Richard Bran­son deal is just the tip of the biotech ice­berg

When Richard Bran­son signed up to join the great SPAC mi­gra­tion of late 2020, you could say he had a rather broad idea of the kind of com­pa­ny he want­ed to take pub­lic. Some­thing “con­sumer fac­ing,” said the icon­ic en­tre­pre­neur in his pa­per­work.

Last week Bran­son end­ed up in the em­brace of 23andMe, sat­is­fied by the ge­net­ic test­ing the com­pa­ny made its name on along the con­sumer front and hap­py to jump in­to drug de­vel­op­ment, where the Glax­o­SmithK­line part­ner is now clear­ly fo­cused.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.